[1]王志刚,刘卓,马小军.丹黄化浊通瘀丸治疗痛风性肾病的临床研究[J].西部中医药,2024,37(04):132-134.[doi:10.12174/j.issn.2096-9600.2024.04.27]
　WANG Zhigang,LIU Zhuo,MA Xiaojun.Clinical Study of Danhuang Huazhuo Tongyu Pills in the Treatment of Gouty Nephropathy[J].Western Journal of Traditional Chinese Medicine,2024,37(04):132-134.[doi:10.12174/j.issn.2096-9600.2024.04.27]
点击复制

丹黄化浊通瘀丸治疗痛风性肾病的临床研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年04期
页码:
132-134
栏目:
临床研究
出版日期:
2024-04-15

文章信息/Info

Title:
Clinical Study of Danhuang Huazhuo Tongyu Pills in the Treatment of Gouty Nephropathy
作者:
王志刚, 刘卓, 马小军
天水市中医医院,甘肃 天水 741000
Author(s):
WANG Zhigang, LIU Zhuo, MA Xiaojun
Tianshui Hospital of TCM, Tianshui 741000, China
关键词:
肾病; 痛风性; 丹黄化浊通瘀丸; 血尿酸; 微球蛋白
Keywords:
nephropathy;  gouty; pills; blood uric acid; -microglobulin
分类号:
R692
DOI:
10.12174/j.issn.2096-9600.2024.04.27
文献标志码:
B
摘要:
目的观察丹黄化浊通瘀丸治疗痛风性肾病的疗效及安全性。 方法选取痛风性肾病患者100例，随机分为观察组和对照组，每组50例。对照组予以调节血脂、止痛等对症处理，并口服别嘌呤醇及坎地沙坦，观察组在此基础上口服丹黄化浊通瘀丸。两组均于治疗12周后评定疗效，并测定治疗前后血尿酸、24 h尿蛋白定量、尿微量白蛋白/肌酐、β2微球蛋白及不良反应发生情况。 结果观察组总有效率［94.0%（47/50）］高于对照组［78.0%（39/50）］（P＜0.05）。两组血尿酸、24 h尿蛋白、尿微量白蛋白/肌酐、β2微球蛋白均较治疗前下降（P＜0.05）；其中血尿酸、β2微球蛋白观察组较对照组下降更明显（P＜0.05）。两组用药前后血常规、肝肾功能未见明显变化，无明显不良反应发生。 结论在常规应用西药治疗的基础上，以丹黄化浊通瘀丸治疗痛风性肾病可明显降低尿酸、减少蛋白尿，改善临床症状，且安全可靠。
Abstract:
ObjectiveTo observe the therapeutic efficacy and safety of Danhuang Huazhuo Tongyu pills (Danhuang Turbidity-resolving Stasis-removing pills) in the treatment of gouty nephropathy. MethodsAll 100 cases of gouty nephropathy were selected and randomly divided into observation group and control group, 50 cases in each group. The control group was treated with symptomatic treatments such as regulating blood lipids, pain relief, and oral allopurinol and candesartan, while the observation group was treated with Danhuang Huazhuo Tongyu pills on the basis of this treatment the control group accepted. Both groups were evaluated after 12 weeks of treatment, and blood uric acid, 24 h urine protein quantification, urine microalbumin/creatinine, β2 micro-globulin and the occurrence of adverse reactions were measured before and after treatment. ResultsThe total effective rate of the observation group [94.0% (47/50)] was higher than that of the control group [78.0% (39/50)] (P<0.05). Serum uric acid, 24-hour urine protein, urinary microalbumin/creatinine, and β2 microglobulin in both groups were all reduced compared with before treatment (P<0.05); among them, serum uric acid and β2 microg-lobulin in the observation group were decreased more than those in the control group (P<0.05). There was no significant changes in blood routine, liver and kidney function before and after treatment in the two groups, and no obvious adverse reactions occurred. ConclusionOn the basis of conventional application of Western medicine, the treatment of gouty nephropathy with the pill can obviously reduce uric acid and proteinuria, improve clinical symptoms, which is safe and reliable.

相似文献/References:

[1]苏筠霞,许筠,苏建平,等.复方萆薢汤治疗尿酸性肾病临床观察*[J].西部中医药,2014,27(07):1.
　SU Junxia,XU Jun,SU Jianping,et al.Clinical Observation on Compound BiXie Tang in Treating Uric Acid Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(04):1.
[2]吴燕.中药外敷联合西药治疗痛风性关节炎 Meta 分析[J].西部中医药,2014,27(09):59.
[3]侯建平,王亚军,严亚峰,等.虎杖提取物抗动物高尿酸血症的实验研究[J].西部中医药,2012,25(05):21.
　HOU Jian-ping,WANG Ya-jun,YAN Ya-feng,et al.Study of Polygonum Cuspidatum Extract on Anti-Hyperuricemia in Rats and Mice[J].Western Journal of Traditional Chinese Medicine,2012,25(04):21.
[4]张勇.四妙永安汤加味治疗急性痛风性关节炎140例[J].西部中医药,2012,25(07):59.
　ZHANG Yong.Clinical Observation on Modified SiMiao YongAnTang in Treating 140 Cases of Acute Gouty Arthritis[J].Western Journal of Traditional Chinese Medicine,2012,25(04):59.
[5]王筝,许庆友△.赵玉庸辨治乙肝相关性肾炎经验*[J].西部中医药,2014,27(03):55.
　WANG Zheng,XU Qingyou.Professor Zhao Yuyong′s Experience of Differentiating and Treating HBV-related Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(04):55.
[6]李 燕,吴三梅.以临床路径为基础的终末期肾病患者心理问题分析与护理对策[J].西部中医药,2016,29(04):115.
　LI Yan,WU Sanmei.Analysis on Nursing Countermeasures and Psychological Problems of the Patients with End-stage Renal Disease Based on Clinical Pathway[J].Western Journal of Traditional Chinese Medicine,2016,29(04):115.
[7]张海林,卢晓君,冯流畅,等.慢性肾脏病湿热型体质易感人群ICAM1基因和IL-10基因启动子多态性研究[J].西部中医药,2018,31(12):1.
　ZHANG Hailin,LU Xiaojun,FENG Liuchang,et al.Study on ICAM1 Gene and IL-10 Gene Promoter Polymorphism of Damp-heat Constitution People Susceptible to Chronic Kidney Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(04):1.
[8]都静,张晓明.血清脂蛋白(α)及胱抑素C与早期糖尿病肾病中医证型的相关性分析[J].西部中医药,2019,32(06):1.
　DU Jing,ZHANG Xiaoming.Analysis on the Correlation between Lipoprotein α,Cystatin C and TCM Patterns of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2019,32(04):1.
[9]杨红云.中医临床护理路径对老年糖尿病肾病患者疗效及血糖水平、体质指数的影响[J].西部中医药,2020,33(01):136.[doi:10.12174/j.issn.1004-6852.2020.01.36]
　YANG Hongyun.Influence of TCM Clinical Nursing Pathway on Clinical Effects, Blood Glucose Level and Body Mass Index of Senile Patients with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2020,33(04):136.[doi:10.12174/j.issn.1004-6852.2020.01.36]
[10]杜霄壤,吴欣,吴孟晋,等.降尿酸方联合别嘌醇片治疗尿酸性肾病的临床研究[J].西部中医药,2020,33(01):1.[doi:10.12174/j.issn.1004-6852.2020.01.01]
　DU Xiaorang,WU Xin,WU Mengjin,et al.Clinical Study on Uric Acid-reducing Prescription Joined with Allopurinol Tablets in the Treatment for Uric Acid Nephropathy[J].Western Journal of Traditional Chinese Medicine,2020,33(04):1.[doi:10.12174/j.issn.1004-6852.2020.01.01]

备注/Memo

备注/Memo:
王志刚（1965—），男，主任医师。研究方向：内分泌疾病的中西医诊治。
更新日期/Last Update: 2024-04-15